Seres Therapeutics MCRB Stock
Seres Therapeutics Price Chart
Seres Therapeutics MCRB Financial and Trading Overview
| Seres Therapeutics stock price | 5.45 USD |
| Previous Close | 5.62 USD |
| Open | 5.59 USD |
| Bid | 3.96 USD x 200 |
| Ask | 6.46 USD x 200 |
| Day's Range | 5.04 - 5.7 USD |
| 52 Week Range | 5.04 - 29.98 USD |
| Volume | 105.03K USD |
| Avg. Volume | 84.28K USD |
| Market Cap | 49.29M USD |
| Beta (5Y Monthly) | 0.095 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.33 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17 USD |
MCRB Valuation Measures
| Enterprise Value | 105.09M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.77414453 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 42.97404 |
| Price/Book (mrq) | 1.8422005 |
| Enterprise Value/Revenue | 91.62 |
| Enterprise Value/EBITDA | -1.254 |
Trading Information
Seres Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.095 |
| 52-Week Change | -61.69% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 29.98 USD |
| 52 Week Low | 5.04 USD |
| 50-Day Moving Average | 7.2 USD |
| 200-Day Moving Average | 12.27 USD |
MCRB Share Statistics
| Avg. Volume (3 month) | 84.28K USD |
| Avg. Daily Volume (10-Days) | 152.5K USD |
| Shares Outstanding | 9.68M |
| Float | 8.47M |
| Short Ratio | 1.41 |
| % Held by Insiders | 11.78% |
| % Held by Institutions | 24.37% |
| Shares Short | 157.33K |
| Short % of Float | 2.13% |
| Short % of Shares Outstanding | 1.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -5839.94% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -38.87% |
| Return on Equity (ttm) | -121.87% |
Income Statement
| Revenue (ttm) | 1.15M USD |
| Revenue Per Share (ttm) | 0.13 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -52304000 USD |
| EBITDA | -83804000 USD |
| Net Income Avi to Common (ttm) | -46899000 USD |
| Diluted EPS (ttm) | -5.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.83M USD |
| Total Cash Per Share (mrq) | 3.08 USD |
| Total Debt (mrq) | 80.5M USD |
| Total Debt/Equity (mrq) | 303.78 USD |
| Current Ratio (mrq) | 1.646 |
| Book Value Per Share (mrq) | 2.763 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -42153000 USD |
| Levered Free Cash Flow (ttm) | -41538248 USD |
Profile of Seres Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 101 Cambridgepark Drive |
| ZIP | 02140 |
| Phone | 617 945 9626 |
| Website | https://www.serestherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 66 |
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Seres Therapeutics Stock
What is a current MCRB stock price?
Seres Therapeutics MCRB stock price today per share is 5.45 USD.
How to purchase Seres Therapeutics stock?
You can buy MCRB shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Seres Therapeutics?
The stock symbol or ticker of Seres Therapeutics is MCRB.
Which industry does the Seres Therapeutics company belong to?
The Seres Therapeutics industry is Biotechnology.
How many shares does Seres Therapeutics have in circulation?
The max supply of Seres Therapeutics shares is 9.68M.
What is Seres Therapeutics Price to Earnings Ratio (PE Ratio)?
Seres Therapeutics PE Ratio is now.
What was Seres Therapeutics earnings per share over the trailing 12 months (TTM)?
Seres Therapeutics EPS is -5.33 USD over the trailing 12 months.
Which sector does the Seres Therapeutics company belong to?
The Seres Therapeutics sector is Healthcare.
Seres Therapeutics MCRB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7161.62 USD — |
+0.7
|
— — | 7044.78 USD — | 7163.12 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12896.68 USD — |
+0.64
|
— — | 12785.35 USD — | 12920.04 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6562.03 USD — |
+0.7
|
— — | 6454.97 USD — | 6563.4 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32406.63 USD — |
+0.62
|
— — | 32125.24 USD — | 32465.34 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}